Overexpression of SOX2 is involved in paclitaxel resistance of ovarian cancer via the PI3K/Akt pathway

Tumor Biology

Volumn 36, Issue 12, 2015, Pages 9823-9828

  Li, Yang ^a   Chen, Kangdong ^a   Li, Lei ^a   Li, Rui ^a   Zhang, Juxin ^a   Ren, Wu ^a  

^a ZHENGZHOU UNIVERSITY   (China)

Author keywords

Apoptosis; Chemoresistance; Ovarian cancer; Proliferation; SKOV3 TAX cells; SOX2

Indexed keywords

PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TRANSCRIPTION FACTOR SOX2; ONCOPROTEIN; SOX2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR SOX;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; BIOSYNTHESIS; CANCER STAGING; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; OVARIAN NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM STAGING; ONCOGENE PROTEIN V-AKT; OVARIAN NEOPLASMS; PACLITAXEL; PHOSPHATIDYLINOSITOL 3-KINASES; SIGNAL TRANSDUCTION; SOXB1 TRANSCRIPTION FACTORS;

EID: 84951273129     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3561-5     Document Type: Article

References (13)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.
2. Vaughan S, Coward JI, Bast RC, Berchuck A, Berek JS. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011;11:719–25.
3. Zhao F, Siu MK, Jiang L, Tam KF, Ngan HY, Le XF, et al. Overexpression of forkhead box protein M1 (FOXM1) in ovarian cancer correlates with poor patient survival and contributes to paclitaxel resistance. PLoS One. 2014;9(11):e113478.
4. Picanco-Castro V, Russo-Carbolante E, Reis LC, Fraga AM, de Magalhaes DA, et al. Pluripotent reprogramming of fibroblasts by lentiviral mediated insertion of SOX2, C-MYC, and TCL-1A. Stem Cells Dev. 2010;20:169–80.
5. Fang X, Yoon JG, Li L, Yu W, Shao J, et al. The SOX2 response program in glioblastoma multiforme: an integrated ChIP-seq, expression microarray, and microRNA analysis. BMC Genomics. 2011;12:11.
6. Alonso MM, Diez-Valle R, Manterola L, Rubio A, Liu D, et al. Genetic and epigenetic modifications of sox2 contribute to the invasive phenotype of malignant gliomas. PLoS One. 2011;6, e26740.
7. Leis O, Eguiara A, Lopez-Arribillaga E, Alberdi MJ, Hernandez-Garcia S, et al. Sox2 expression in breast tumours and activation in breast cancer stem cells. Oncogene. 2011;31:1354–65.
8. Floor S, van Staveren WC, Larsimont D, Dumont JE, Maenhaut C. Cancer cells in epithelial-to-mesenchymal transition and tumor-propagating-cancer stem cells: distinct, overlapping or same populations. Oncogene. 2011;30:4609–21.
9. Fang X, Yu W, Li L, Shao J, Zhao N, et al. ChIP-seq and functional analysis of the SOX2 gene in colorectal cancers. OMICS. 2010;14:369–84.
10. Chen Y, Shi L, Zhang L, Li R, Liang J, Yu W, et al. The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer. J Biol Chem. 2008;283:17969–78.
11. Jiang L, Siu MK, Wong OG, Tam KF, Lu X, Lam EW, et al. iASPP and chemoresistance in ovarian cancers: effects on paclitaxel-mediated mitotic catastrophe. Clin Cancer Res. 2011;17(21):6924–33.
12. Deraco M, Baratti D, Laterza B. Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancer. Eur J Surg Oncol. 2011;37:4–9.
13. Jia X, Li X, Xu Y, Zhang S, Mou W, et al. SOX2 promotes tumorigenesis and increases the anti-apoptotic property of human prostate cancer cell. J Mol Cell Biol. 2011;3:230–8.